JP2017501202A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501202A5
JP2017501202A5 JP2016544410A JP2016544410A JP2017501202A5 JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5 JP 2016544410 A JP2016544410 A JP 2016544410A JP 2016544410 A JP2016544410 A JP 2016544410A JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5
Authority
JP
Japan
Prior art keywords
nicotinamide
pyridin
cyano
fluoro
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544410A
Other languages
English (en)
Japanese (ja)
Other versions
JP6475252B2 (ja
JP2017501202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/010006 external-priority patent/WO2015103453A1/en
Publication of JP2017501202A publication Critical patent/JP2017501202A/ja
Publication of JP2017501202A5 publication Critical patent/JP2017501202A5/ja
Application granted granted Critical
Publication of JP6475252B2 publication Critical patent/JP6475252B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016544410A 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物 Expired - Fee Related JP6475252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923403P 2014-01-03 2014-01-03
US61/923,403 2014-01-03
PCT/US2015/010006 WO2015103453A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds

Publications (3)

Publication Number Publication Date
JP2017501202A JP2017501202A (ja) 2017-01-12
JP2017501202A5 true JP2017501202A5 (enExample) 2018-12-13
JP6475252B2 JP6475252B2 (ja) 2019-02-27

Family

ID=52355270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544410A Expired - Fee Related JP6475252B2 (ja) 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物

Country Status (21)

Country Link
US (1) US9169252B2 (enExample)
EP (1) EP3089973B1 (enExample)
JP (1) JP6475252B2 (enExample)
KR (1) KR20160101191A (enExample)
CN (1) CN106061967B (enExample)
AR (1) AR098991A1 (enExample)
AU (1) AU2015204045A1 (enExample)
CA (1) CA2935329A1 (enExample)
CL (1) CL2016001706A1 (enExample)
EA (1) EA201691343A1 (enExample)
ES (1) ES2804707T3 (enExample)
IL (1) IL246474A0 (enExample)
MA (1) MA39162A1 (enExample)
MX (1) MX2016008723A (enExample)
PE (1) PE20161292A1 (enExample)
PH (1) PH12016501164A1 (enExample)
SG (1) SG11201605340QA (enExample)
TN (1) TN2016000271A1 (enExample)
TW (1) TW201609693A (enExample)
UY (1) UY35935A (enExample)
WO (1) WO2015103453A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503397YA (en) 2012-11-08 2015-05-28 Bristol Myers Squibb Co Heteroaryl substituted pyridyl compounds useful as kinase modulators
US9546153B2 (en) 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN109045032A (zh) 2014-01-01 2018-12-21 麦迪威森技术有限责任公司 氨基吡啶类化合物和使用方法
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN109641906B (zh) * 2015-06-24 2021-10-01 百时美施贵宝公司 杂芳基取代的氨基吡啶化合物
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
EP3313844B1 (en) * 2015-06-24 2020-08-26 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
GB201518456D0 (en) 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
TWI733982B (zh) * 2017-02-16 2021-07-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
ES2921020T3 (es) * 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
DK3682881T3 (da) 2017-09-14 2026-05-11 Daiichi Sankyo Co Limited Forbindelse med cyklisk struktur
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
JP7366031B2 (ja) 2017-09-22 2023-10-20 カイメラ セラピューティクス, インコーポレイテッド タンパク質分解剤およびそれらの使用
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ii
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
CA3090275A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP7682154B2 (ja) * 2019-08-06 2025-05-23 ブリストル-マイヤーズ スクイブ カンパニー Irak4阻害剤として有用な二環ヘテロ環式化合物
EP4072591A4 (en) 2019-12-10 2024-06-05 Kymera Therapeutics, Inc. IRAQ DEGRADER AND USES THEREOF
JP2023509366A (ja) 2019-12-17 2023-03-08 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP7682191B2 (ja) 2020-02-03 2025-05-23 ブリストル-マイヤーズ スクイブ カンパニー Irak4阻害剤として有用な三環ヘテロアリール化合物
US12528814B2 (en) 2020-02-19 2026-01-20 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2022147465A1 (en) 2020-12-30 2022-07-07 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
WO2023008973A1 (ko) * 2021-07-29 2023-02-02 프라비바이오 주식회사 신규 벤젠 유도체 및 이의 면역억제 관련 용도
EP4367118B1 (en) 2021-08-18 2025-01-29 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc IRAK joints and their uses
WO2025151602A1 (en) * 2024-01-11 2025-07-17 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
WO2025151728A1 (en) * 2024-01-12 2025-07-17 Bristol-Myers Squibb Company Ligand directed degrader of irak4
CN118388401B (zh) * 2024-06-28 2024-08-20 成都凯斯坦生物医药有限公司 一种4-氨基-2-氯烟醛的制备方法
CN118641677B (zh) * 2024-08-16 2024-11-05 北京京丰制药集团有限公司 尼可刹米原料中杂质的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
DE60232510D1 (de) 2001-06-15 2009-07-16 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
EP1518855B1 (en) 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
AU2004257260A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP2164841A1 (en) 2007-06-08 2010-03-24 Bayer CropScience SA Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
AU2009320683B2 (en) * 2008-11-28 2012-07-19 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
JP2012529535A (ja) * 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
JP5770198B2 (ja) 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ.ベー. オピオイド受容体調節因子としてのフェノキシ置換ピリミジン
JPWO2011093501A1 (ja) 2010-02-01 2013-06-06 日本ケミファ株式会社 Gpr119作動薬
BR112013027787A2 (pt) 2011-04-29 2017-06-27 Icahn School Med Mount Sinai compostos, composição farmacêutica, método para tratar um distúrbio proliferativo celular, método para tratar um distúrbio neurológico, métodos para inibir uma ou mais quinases, método para inibir a proliferação celular de células cancerosas, método para induzir a morte celular de células cancerosas, método para induzir a apoptose de células cancerosas, método para induzir a apoptose em uma célula e métodos para produzir compostos
US9074384B2 (en) * 2011-07-27 2015-07-07 Intex Recreation Corp. Combined swimming pool ladder structure
ES2575604T3 (es) 2012-01-13 2016-06-29 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa
JP6109195B2 (ja) * 2012-01-13 2017-04-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼ阻害剤として有用な複素環置換されたピリジル化合物
CN104169275B (zh) 2012-01-13 2017-06-09 百时美施贵宝公司 用作激酶抑制剂的三唑取代的吡啶化合物
SG11201503397YA (en) * 2012-11-08 2015-05-28 Bristol Myers Squibb Co Heteroaryl substituted pyridyl compounds useful as kinase modulators
AR093403A1 (es) 2012-11-08 2015-06-03 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
US9546153B2 (en) * 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators

Similar Documents

Publication Publication Date Title
JP6475252B2 (ja) ヘテロアリール置換のニコチンアミド化合物
JP2018522859A5 (enExample)
JP7576552B2 (ja) イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
AU2010333804B2 (en) Fused heteroaromatic pyrrolidinones as syk inhibitors
CN111372931B (zh) 作为蛋白激酶抑制剂的杂环化合物
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP6689871B2 (ja) Fgfr阻害剤としての二環式複素環
TWI911225B (zh) 治療性化合物及其用途
KR102339227B1 (ko) Gsk-3 억제제
AU2017378943A1 (en) FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
JP2016523911A5 (enExample)
AU2010335556A1 (en) Imidazopyridine derivatives as JAK inhibitors
JP2018524331A5 (enExample)
SG184822A1 (en) Fused bicyclic kinase inhibitors
RS54823B1 (sr) Derivati piperidin-4-il azetidina kao inhibitori jak1
JP2013523884A5 (enExample)
KR20190019187A (ko) 헤테로아릴 치환된 아미노피리딘 화합물
JP2022545364A5 (enExample)
JP2023510874A (ja) 置換ピラゾロ-ピリミジンおよびその使用
AU2021405620A1 (en) Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
CN107108653B (zh) 吡唑并噻唑化合物及医药
US9150592B2 (en) Heterocyclic nuclear hormone receptor modulators
WO2025017078A1 (en) New pyrazolopyridine derivatives
CA3257173A1 (en) Pyrrolidine derivatives useful as NF-κB induction kinase inhibitors
KR102133595B1 (ko) 단백질 키나제 억제제로서의 헤테로고리 화합물